Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 October 2020Website:
http://praxismedicines.comNext earnings report:
07 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 20:30:43 GMTDividend
Analysts recommendations
Institutional Ownership
PRAX Latest News
BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report its financial results from the third quarter ended September 30, 2024, before the financial markets open on Wednesday, November 6, 2024.
Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.
BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that that it will present preclinical and clinical data from three of its epilepsy programs at the International League Against Epilepsy (ILAE) 15th European Epilepsy Congress (EEC), being held from September 7 to 11, 2024 in Rome, Italy.
Placebo-adjusted monthly motor seizure reduction of 46% during double-blind period Over 30% of patients achieved seizure freedom status while on relutrigine Meaningful gains observed in alertness, communication and seizure severity 75% reduction in median seizure rate seen for patients in the long-term extension Registrational phase of the EMBOLD study for SCN2A and 8A initiated BOSTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today shared positive topline results for its Phase 2, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients.
BOSTON, Mass., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will share the topline results from the Phase 2 EMBOLD study of relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies (DEEs) on Tuesday, September 3, 2024, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:00 a.m. ET to discuss the trial results.
Praxis Precision Medicines (PRAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Praxis Precision Medicines, Inc. (NASDAQ:PRAX ) Q2 2024 Earnings Conference Call August 13, 2024 8:00 AM ET Company Participants Marcio Souza - President and Chief Executive Officer Tim Kelly - Chief Financial Officer Daniel Ferry - Investor Relations, Life Science Advisors Conference Call Participants Yasmeen Rahimi - Piper Sandler Joon Lee - Truist Securities Francois Brisebois - Oppenheimer Yatin Suneja - Guggenheim Ritu Baral - TD Cowan Joel Beatty - Baird Ami Fadia - Needham Douglas Tsao - HC Wainwright & Co Kambiz Yazdi - Jeffries Operator Good day, thank you for standing by. Welcome to the Praxis Precision Medicines' Second Quarter 2024 Corporate Update Conference Call.
Praxis Precision Medicines, Inc. (PRAX) came out with a quarterly loss of $1.74 per share versus the Zacks Consensus Estimate of a loss of $2.38. This compares to loss of $7.35 per share a year ago.
Praxis Precision Medicines (PRAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for CNS disorders, will be attending three upcoming conferences, as announced today.
- 1(current)
What type of business is Praxis Precision Medicines?
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
What sector is Praxis Precision Medicines in?
Praxis Precision Medicines is in the Healthcare sector
What industry is Praxis Precision Medicines in?
Praxis Precision Medicines is in the Biotechnology industry
What country is Praxis Precision Medicines from?
Praxis Precision Medicines is headquartered in United States
When did Praxis Precision Medicines go public?
Praxis Precision Medicines initial public offering (IPO) was on 16 October 2020
What is Praxis Precision Medicines website?
https://praxismedicines.com
Is Praxis Precision Medicines in the S&P 500?
No, Praxis Precision Medicines is not included in the S&P 500 index
Is Praxis Precision Medicines in the NASDAQ 100?
No, Praxis Precision Medicines is not included in the NASDAQ 100 index
Is Praxis Precision Medicines in the Dow Jones?
No, Praxis Precision Medicines is not included in the Dow Jones index
When was Praxis Precision Medicines the previous earnings report?
No data
When does Praxis Precision Medicines earnings report?
The next expected earnings date for Praxis Precision Medicines is 07 November 2024